Phaseline

Companies › EveryONE Medicines

EveryONE Medicines: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Individualized ASO
Antisense oligonucleotide targeting unique genetic variants in CNS conditions
–Phase 1Pediatric SDLT CNS Disorders–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07410143Individualized ASOPhase 1Pediatric SDLT CNS DisordersNeurologySep 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.